RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC are lacking and healthcare professionals must consider several factors, including serum markers, patient age and pre-existing comorbidities when choosing between second-line hormonal therapy and chemotherapy for treatment of CRPC. It is critical for healthcare professionals involved in the care of patients with CRPC to understand and utilize the current optimal methods for defining, assessing and treating this condition.

To address the need for current education on CRPC, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education live Webcast titled Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease on Thursday March 25, 2010 from 12:00 PM to 1:00 PM ET. This activity, which is supported by educational grants from sanofi aventis and Genentech, is certified for physicians, pharmacists and nurses.

Robert Dreicer, MD, MS, FACP, Chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine in Cleveland, OH will serve as expert faculty for this live Webcast.

Healthcare professionals can register today by visiting www.ProstateEducation.com.